What Researchers Did
This article describes rhinocerebral mucormycosis and the adjunctive role of hyperbaric oxygen therapy in its treatment.
What They Found
Rhinocerebral mucormycosis is an acutely fatal fungal infection, typically affecting diabetic or immunocompromised patients. The authors found that adjunctive hyperbaric oxygen (HBO) therapy appears promising, as oxygen in sufficient concentrations is fungicidal and improves tissue survival by decreasing acidosis.
What This Means for Canadian Patients
Canadian patients diagnosed with rhinocerebral mucormycosis may benefit from a comprehensive treatment plan that includes aggressive surgical debridement, high-dose amphotericin-B, and control of underlying conditions. Adjunctive hyperbaric oxygen therapy could be considered as a promising additional treatment option to improve outcomes.
Canadian Relevance
This study has no specific Canadian connection or data.
Study Limitations
A limitation of this article is that it describes a treatment modality without presenting original research data or a controlled study to quantify the efficacy of hyperbaric oxygen therapy.